Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype

Loss of heterozygosity (LOH) in loci of the 10q23 region that harbor the PTEN gene and mutations in the sequence of this gene have been found in several primary human tumors including breast carcinomas, suggesting that this gene could be implicated in their pathogenesis. We investigated allelic losses in microsatellites of the 10q23 region, and their correlations with nine pathologic parameters in 105 breast carcinomas. The LOH analysis was performcd by amplifying DNA by PCR, using five markers of the 10q23 region (D10S1687, D10S541, D10S2491, D10S583 and D10S571). LOH in at least one marker of the PTEN region was found in 29.5% of tumors. The statistical comparison between carcinomas with and without LOH in terms of the pathologic parameters showed significant differences in age (p=0.03), lymph node metastases (p=0.02), and higher histological grade (p=0.02); a trend toward significance was found for progesterone receptors (p=0.05). LOH in an individual marker and statistically significant relationships to tumor characteristics were observed at locus D10S541 for lymph node metastases (p=0.04), at D10S2491 (intragenic to the PTEN gene) for lymph node metastases (p=0.02), and at D10S583 for progesterone receptors (p=0.01) and for high grade (p=0.03). These results suggest the PTEN gene, or other genes of the 10q23 region, could be functionally related to breast cancer, probably influencing the development of histological features associated with poor prognosis.

[1]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[2]  Å. Borg,et al.  Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer. , 1996, British Journal of Cancer.

[3]  J. Weissenbach,et al.  Loss of the chromosomal region 10q23-25 in prostate cancer. , 1995, Cancer research.

[4]  W. Isaacs,et al.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. , 1998, Cancer research.

[5]  Audenino Rg.  [Malignant tumors of the breast]. , 1960, El Dia medico.

[6]  W. Cavenee,et al.  The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. , 1998, Cancer research.

[7]  J. Herman,et al.  Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers , 1998, Oncogene.

[8]  Hanlee P. Ji,et al.  Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis. , 1997, American journal of human genetics.

[9]  M. Beckmann,et al.  Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. , 1996, British Journal of Cancer.

[10]  A. Børresen-Dale,et al.  Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. , 1998, Cancer research.

[11]  R. Sutphen,et al.  The genetic basis of Cowden’s syndrome: three novel mutations in PTEN/MMAC1/TEP1 , 1998, Human Genetics.

[12]  B. Gusterson,et al.  Combined loss of BRCA1/BRCA2 in grade 3 breast carcinomas , 1996, The Lancet.

[13]  J. Ott,et al.  The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. , 1997, American journal of human genetics.

[14]  G. Wahl,et al.  Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. , 1996, Cancer research.

[15]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[16]  Kathleen R. Cho,et al.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. , 1997, Cancer research.

[17]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[18]  D. Birnbaum,et al.  Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. , 1997, Cancer research.

[19]  J. Bruce,et al.  Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.

[20]  I. Bièche,et al.  Genetic alterations in breast cancer , 1995, Genes, chromosomes & cancer.

[21]  J. Boyd,et al.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. , 1997, Cancer research.

[22]  G. Mills,et al.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. , 1997, Cancer research.

[23]  P. Devilee,et al.  Somatic genetic changes in human breast cancer. , 1994, Biochimica et biophysica acta.

[24]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[25]  大藤 道衛.  Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus , 1995 .

[26]  O. Cussenot,et al.  PTEN/MMAC1/TEP1 involvement in primary prostate cancers , 1998, Oncogene.

[27]  M. P. Neal.  MALIGNANT TUMORS OF THE MALE BREAST , 1933 .

[28]  A. Berchuck,et al.  PTEN/MMAC1 mutations in endometrial cancers. , 1997, Cancer research.

[29]  R. McLendon,et al.  Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. , 1995, Oncogene.

[30]  C. Eng,et al.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.

[31]  Baljit Singh,et al.  Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus , 1998, Genes, chromosomes & cancer.

[32]  R. Rendi.  Na+,K+ requiring ATPase. V. Preparation and assay of a solubilized Na+ stimulated ADP-ATP exchange activity. , 1970, Biochimica et biophysica acta.

[33]  J. Herman,et al.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. , 1997, Cancer research.

[34]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[35]  H. Hibshoosh,et al.  Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas , 1998, Oncogene.

[36]  A. Sakurada,et al.  PTEN1 is frequently mutated in primary endometrial carcinomas , 1997, Nature Genetics.

[37]  C. Larsson,et al.  Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. , 1997, Cancer research.

[38]  Kenneth M. Yamada,et al.  Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. , 1998, Science.

[39]  R. McLendon,et al.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas. , 1997, Cancer research.

[40]  R. Parsons,et al.  The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. , 1998, Cancer research.